96
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
OPN-305
For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
Research Site, New York
Research Site, The Bronx
Research Site, Tampa
Research Site, Houston
Lead Sponsor
M.D. Anderson Cancer Center
OTHER
Montefiore Medical Center
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
New York Presbyterian Hospital
OTHER
Opsona Therapeutics Ltd.
INDUSTRY